Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;88(1):105074.
doi: 10.1016/j.jbspin.2020.09.006. Epub 2020 Sep 17.

Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. Joint Bone Spine. 2020;87:191-93

Matheus Vieira  1 , Georgina Maalouf  1 , Milena Hasan  2 , Alexandre Le Joncour  1 , Esma Karkeni  2 , Merwan Idir  1 , Damien Amelin  1 , Joe-Elie Salem  3 , Paul Gougis  3 , Jean-Marc Lacorte  4 , Lucie Biard  5 , Olivier Benveniste  1 , Patrice Cacoub  1 , David Saadoun  1 , Yves Allenbach  6 ; behalf of DIMICOVID
Affiliations
Comment

Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. Joint Bone Spine. 2020;87:191-93

Matheus Vieira et al. Joint Bone Spine. 2021 Jan.
No abstract available

Keywords: COVID-19; Coronavirus disease 2019; Cytokines; IL-6; Prognosis; TNF.

PubMed Disclaimer

Comment in

Comment on

References

    1. Quartuccio L., Semerano L., Benucci M. Urgent avenues in the treatment of COVID-19: targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020;87:191–193. - PMC - PubMed
    1. Jamilloux Y., Henry T., Belot A. Should we stimulate or suppress immune responses in COVID-19?. Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19:102567. - PMC - PubMed
    1. Hadjadj J., Yatim N., Barnabei L. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724. doi: 10.1126/science.abc6027. - DOI - PMC - PubMed
    1. Giamarellos-Bourboulis E.J., Netea M.G., Rovina N. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell host microbe. 2020 doi: 10.1016/j.chom.2020.04.009. - DOI - PMC - PubMed
    1. Toniati P., Piva S., Cattalini M. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19:102568. - PMC - PubMed